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Background and purpose: Intensity-modulated radiotherapy (IMRT) credentialing for a EORTC study was
performed using an anthropomorphic head phantom from the Radiological Physics Center (RPC; RPCPH). Institutions
were retrospectively requested to irradiate their institutional phantom (INSTPH) using the same treatment plan in
the framework of a Virtual Phantom Project (VPP) for IMRT credentialing.
Materials and methods: CT data set of the institutional phantom and measured 2D dose matrices were requested
from centers and sent to a dedicated secure EORTC uploader. Data from the RPCPH and INSTPH were thereafter
centrally analyzed and inter-compared by the QA team using commercially available software (RIT; ver.5.2;
Colorado Springs, USA).
Results: Eighteen institutions participated to the VPP. The measurements of 6 (33%) institutions could not be
analyzed centrally. All other centers passed both the VPP and the RPC ±7%/4 mm credentialing criteria. At
the 5%/5 mm gamma criteria (90% of pixels passing), 11(92%) as compared to 12 (100%) centers pass the
credentialing process with RPCPH and INSTPH (p = 0.29), respectively. The corresponding pass rate for the 3%/3 mm
gamma criteria (90% of pixels passing) was 2 (17%) and 9 (75%; p = 0.01), respectively.
Conclusions: IMRT dosimetry gamma evaluations in a single plane for a H&N prospective trial using the INSTPH
measurements showed agreement at the gamma index criteria of ±5%/5 mm (90% of pixels passing) for a small
number of VPP measurements. Using more stringent, criteria, the RPCPH and INSTPH comparison showed disagreement.
More data is warranted and urgently required within the framework of prospective studies.
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The delivery of radiation therapy (RT) to Head and Neck
(H&N) cancers is highly complex and challenging in
terms of tumour delineation and treatment delivery.
Recognizing the complexity of these treatments, espe-
cially delivered with Intensity Modulated RT (IMRT) in a
multi-institutional clinical trial setting, the National
Cancer Institute (NCI) funded clinical trial groups estab-
lished an IMRT credentialing program administered by
the Radiological Physics Center (RPC). Up to 2011, the
RPC has evaluated 1139 anthropomorphic Head and Neck
(H&N) IMRT phantom irradiations as a part of its creden-
tialing program for participation in NCI funded clinical
trials that allow the use of IMRT [1]. Early in the creden-
tialing process, it was reported that nearly 28% of the in-
stitutions could not pass this irradiation study on their
first attempt with generous acceptance criteria of ±7% for
dose in a low gradient and/or ±4 mm distance to agree-
ment in high gradient region [2]. More recently, a follow-
up publication has shown that the pass rate has increased
to nearly 82% indicating an improved implementation of
IMRT over the past 10 years [3]. Even with these improve-
ments, it is of interest to note that 18% of irradiations did
not pass this phantom study. Molineu et al. also reported
that after 12 years of credentialing, an analysis of the irra-
diations showed that the credentialing failure rate doubled
when the criteria was reduced from ±7%/4 mm to ± 5%/
4 mm [3]. As such, delivering advanced technology RT for
H&N cancers in clinical trials remains challenging and re-
quires RT credentialing before a facility is allowed to par-
ticipate in a specific clinical trial.
Conducting clinical trial research in the cooperative
group setting requires a set of defined standards and
consistent treatments for investigator and site participa-
tion in order for the trial results to be valid and extend-
able to the broader oncology community. Even though
the benefits of QA and RT credentialing have been dem-
onstrated [4-6], there can be resistance to credentialing
requirements as they are sometimes perceived to be an
unnecessary burden, simply due to the extra effort needed
to perform the credentialing requirements. Despite an in-
stitution’s concern that credentialing requirements, that
may include a phantom irradiation study, completion of a
questionnaire or having the treatment plan approved prior
to commencing the RT treatment, are burdensome, this
extra burden has been shown to reduce deviations by min-
imizing the patient data uncertainty used to analyze the
trial outcomes. There are many ways to credential institu-
tions to participate in clinical trials and different methods
should be investigated to find improved and more efficient
processes. We undertook a study to determine whether
the use of an institution’s own phantom and QA mea-
surements analyzed centrally by a dedicated QA team
could be correlated with the end-to-end anthropomorphicphantom irradiation results for Complex Dosimetry
Checks (CDC).
The QA Strategic Committee from the European
Organization for the Research and Treatment of Cancer
(EORTC) thus decided to compare the measured dose
distributions obtained using the anthropomorphic IMRT
H&N phantom irradiation results from the RPC for a
new H&N EORTC study (22071-24071) to each institu-
tion’s own IMRT QA measurements obtained using their
pre-treatment verification methodology. This paper pre-
sents a comparison of the RPC’s measured planar dose
distribution results and the institutional phantom IMRT
QA measurement results for the EORTC Virtual Phantom
Project (VPP). This work is presented as collaboration
between these two QA centers in the framework of the
Global Harmonization Group, which thrive to harmonize
and improve the quality assurance of radiation therapy
implemented worldwide (http://www.rtqaharmonisation.
org/).
Patients and methods
The planned QA activities of a non-activated random-
ized phase III H&N trial, assessing postoperative chemo-
radiation in combination with anti EGFR-antibody vs.
postoperative chemoradiation in squamous cell carcin-
omas (EORTC 22071-24071), included a facility question-
naire, an External Reference Dosimetry Audit (ERDA), a
Dummy Run, Individual Case reviews and CDCs for
IMRT (i.e. QART level 5 [7]). This phase III study was ap-
proved by institutional ethics committee of all participat-
ing centers (Additional file 1). Prior to an institution being
allowed to use IMRT to treat patients on this trial it had
to successfully complete an IMRT CDC in accordance
with the QART protocol guidelines. As such, 18 EORTC
centers participated in the IMRT credentialing process be-
fore their activation to the trial.
This study compares some of the dosimetry measure-
ments obtained as a part of the CDCs performed by the
RPC (Houston, USA; http://rpc.mdanderson.org) using
their IMRT H&N anthropomorphic phantom (RPCPH
CDC) and dosimetry measurements performed by each
institution using their own IMRT QA phantom and plan
from the RPC phantom irradiation (INSTPH CDC). The
RPCPH CDC’s phantom dosimetry insert contains eight
Thermo Luminescent Dosimeters (TLDs) within the pri-
mary and secondary PTVs and one organ at risk (OAR)
(Figure 1). The phantom has two radiochromic films go-
ing through the primary PTV in the axial and sagital
planes. Only the RPCPH CDC measured dose distribution
data in the sagital plane were used for comparison in this
study. The INSTPH CDCs used in the analyses included
2D dose measurements in coronal and/or sagital planes as
supplied by the institutions. All dosimetry measurements,
RPCPH and INSTPH CDCs, were collected and analyzed as
Figure 1 Cross-sectional view of the insert in the axial film plane.
Table 1 Institutional treatment planning systems and
anthropomorphic quality assurance phantoms
performing the VPP for 12 EORTC centers
Treatment planning systems Number (%) Type of
computational
algorithms
Eclipse 7 (58.3) AAA
Tomotherapy 2 (16.7) CSA
Pinnacle 2 (16.7) CC
Monaco 1 (8.3) Monte Carlo
Type of quality assurance phantom
and measurement tool
Number (%) Registration
method
Delta4 4 (33.3) Central
Cheese fantom + film 1 (8.3) Automatic
Octavius + 2D-array 4 (33.3) Central
Portal Dosimetry 2 (16.7) Central
Solid water slabs + film 1 (8.3) Automatic
Abbreviations: CSA/AAA: Convolution superposition algorithm-Analytical anisotropic
algorithm; CC: Collapsed Cone algorithm.
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performed for each CDC. The RPCPH CDC normalization
was performed using the measured TLD doses whereas
the INSTPH CDC normalization was to the dose distribu-
tion’s maximum dose. All INSTPH CDCs beams were
measured using the gantry angle as defined in the clinical
treatment plan and all, except one, were measurements of
all fields combined. All measurement data were centrally
collected, compared and analyzed at the EORTC’s QA
center.
Dose distributions were compared using the gamma
index function described by Low et al. [8], normalized
using the predicted dose. The standard RPCPH CDC ana-
lysis used an acceptance criterion of ±7%/4 mm criteria
established in conjunction with clinical trial groups for both
the axial and sagital film planes. For this study, the RPC
provided 2D gamma analyses to the EORTC, using ±3%/
3 mm, ±5%/5 mm and ±7%/4 mm criteria, for 18 phantom
irradiations. The gamma evaluation was performed using
a global comparison method and a prescription dose of
6.6 Gy (RPC’s dose level for CDC) to which the dose was
normalized. The dose distribution area evaluated was a
rectangular film area encompassing the primary PTV and
OAR.
For the INSTPH CDCs, each EORTC institution was
asked to CT scan their in-house IMRT QA phantom
and recalculate a hybrid treatment plan dose distribution
for their INSTPH CDC, using the same treatment plan-
ning system (TPS), monitor units and fields as used for
the RPC phantom irradiation. The number of planes and
point doses evaluated for each institution varied between
multiple planes of data being provided to a single planeof data being used for this analysis. The various differ-
ent TPSs and INSTPH CDC measurement systems used
in this VPP are shown in Table 1. The INSTPH CDC was
performed at each of the EORTC institutions and one
or more 2D dose distributions were generated. The TPS
DICOM-RT datasets of the INSTPH CDC, and the institu-
tion’s IMRT QA measurement system datasets were col-
lected and compressed into one file and sent to the EORTC
virtual QA platform (https://uploader.eortc.be/qat/). Using
the institution’s TPS and dosimetry QA measurement data,
the institution’s TPS and QA measurement comparisons
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Radiological Imaging Technology software 113 (RIT; ver.5.2;
Colorado Springs, USA). The RPC analysis used an in-
house software with a rectangular area of interest while
EORTC used the RIT113 software from RIT disregarding
the dose below 5% of the prescribed dose.
The calculated and measured INSTPH CDC dose dis-
tributions were compared using a global dose gamma
index evaluation with ±3%/3 mm, ±5%/5 mm and ±7%/
4 mm criteria and the maximum measured dose as the
normalization point (this absolute dose was considered
as the 100% dose in the gamma analysis) instead of the
prescription dose as used in the RPC analysis. The par-
ticipating institutions provided their film dosimetry cali-
bration curve to correctly convert grey-scale to dose. No
rescaling of the calculated dose distributions was per-
formed whereas the RPC measured dose distributions
were rescaled to the measured TLD dose in the primary
PTV. Institutions used the Delta4, 2D-array and portal
device as absolute dose measurement tools (Table 2).
Except for the institution film dosimetry, the dose dis-
tributions were registered using the “central registration”
option as the isocenter corresponded to the center of
the measurement device. Due to lack of usable reference
points an automatic registration option based on best
guess was used for film dosimetry that may have intro-
duced some rotational uncertainty in the registration ofTable 2 RPC and VPP average percentage of pixels passing th
for 12 institutions of the EORTC for IMRT complex dosimetry
RPC
Institution number 3%/3 mm
(%) RPCPH
5%/5 mm
(%) RPCPH
7%/4 mm
(%) RPCPH
Number
verified fie
1 89.3 99.9 99.8 Combine
2 62.9 82.0 91.2 Combine
3 78.1 99.9 97.8 Combine
4 84.7 98.2 99.5 Combined
5 80.1 98.2 99.3 Combined
6 96.4 99.8 99.9 9
7 96.5 99.8 100.0 Combine
8 89.1 96.9 98.1 Combine
9 73.5 91.9 95.5 Combine
10 79.6 94.1 98.8 Combine
11 89.9 98.9 99.7 Combine
12 72.5 93.0 96.8 Combine
CDC
Pass at 80% pixel level 7 12 12
Pass at 90% pixel level 2 11 12
Pass at 95% pixel level 2 8 11
Abbreviations: RPC: Radiological Physics Center; VPP: Virtual Phantom Project; SD: St
measurement of all fields is made a: measured twice.the two dose distributions, but is not anticipated to sig-
nificantly influence the results.
RPC and VPP gamma indexes were compared using the
Wilcoxon signed ranks test. Differences were regarded as
statistically significant at the p < 0.05 level. Analyses were
performed on the Statistical Package for Social Sciences
(SPSS, Ver. 18.0, SPSS Inc., Chicago, IL).
Results
RPCPH CDC phantom study
Table 2 details the RPC dose analyses for 12 phantom irra-
diations. In total, 36 RPC dose distribution gamma index
evaluations were calculated for this study and compared
to the dose distributions gamma evaluations from the
12 EORTC institutions that provided their IMRT data
using ±3%/3 mm, ±5%/5 mm and ±7%/4 mm at 80%, 90%
and 95% pixel pass rates for each criteria level. Ten (83%)
and 1 (8%) of the 12 RPC phantom irradiations, using the
sagital film plane only, did not pass the gamma criteria
of ±3%/3 mm and ±5%/5 mm (90% of the pixels meeting
the criteria), respectively. None of the films in the 12 irra-
diations failed the RPC gamma criteria of ±7%/4 mm (at
either the 80% (current) or 95% of pixels passing) as noted
in Table 2. Table 3 details the RPC gamma evaluation of
the sagittal plane dose distribution and the institution’s
VPP gamma results (represented as the average percent of
pixels passing each defined criteria).e gamma criteria at 3%/3 mm, 5%/5 mm and 7%/4 mm
checks
VPP
of
lds
Measurement
device
3%/3 mm (%)
[SD] INSTPH
5%/5 mm (%)
[SD] INSTPH
7%/4 mm (%)
[SD] INSTPH
d Delta4 100.0 [-] 100.0 [-] 100.0 [-]
d PTW 2D-array 93.2 [-] 99.0 [-] 99.4 [-]
d PTW 2D-array 90.8 [0.9] 100 [0.2] 100 [0.3]
a PTW 2D-array 84.1 [1.9] 95.7 [0.6] 96.4 [0.7]
a Varian Portal 96.5 [3.3] 99.8 [0.3] 100.0 [0.0]
Varian Portal 96.6 [2.2] 99.4 [1.3] 100.0 [0.0]
d PTW 2D-array 85 [1.3] 96.6 [0.6] 97.3 [0.5]
d EDR2-Film 89.1 [-] 99.3 [-] 99.9 [-]
d Delta4 99.5 [-] 100.0 [-] 100.0 [-]
d Delta4 98.4 [-] 100.0 [-] 100.0 [-]
d EDR2-Film 92.2 [-] 97.0 [-] 100.0 [-]
d Delta4 97.1 [-] 100.0 [-] 100.0 [-]
12 12 12
9 12 12
6 12 12
andard Deviation; CDC, complex dosimetry checks. Combined: A combined
Table 3 Wilcoxon signed ranks test of the RPC sagital film plane and VPP gamma indexes mean values
3%/3 mm (%) [SD] p value 5%/5 mm (%) [SD] p value 7%/4 mm (%) [SD] p value
0.02 0.21 0.08
RPC (RPCPH) 82.7 [10.2] 96.1 [5.3] 98.0 [2.6]
VPP (INSTPH) 93.5 [5.4] 98.9 [1.5] 99.4 [1.2]
Abbreviations: RPC: Radiological Physics Center; VPP: Virtual Phantom Project.
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An INSTPH CDC was performed by 12 centers (Table 2).
Table 2 details the average dose distribution gamma
evaluation percent of pixels meeting the 3 different cri-
teria levels for the multiple planes of data provided by
each institution to the EORTC QA team representing the
multiple gantry angles for the entire dose delivery. The
IMRT QA measurements from six out of 18 institutions
(33%) could not be analyzed centrally at the EORTC for
the following reasons. Downloaded files (in .opd, .asc
or .dcm format) from 2 centers could not be read by the
RIT software, a header file from a Tomotherapy data
file was missing in 2 other centers, missing files with the
scanned measurement file uploaded to the digital plat-
form in another center and finally a missing .opg MatriXX
measurement file that could not be uploaded in an add-
itional center. The inability to receive and analyze the
institution’s TPS and dosimetry data for a third of the in-
stitutions warrants further investigation and an improved
data receipt method before the VPP can be implemented.
In total, 20 INSTPH dose maps from 12 EORTC insti-
tutions were analyzed using gamma QA criteria of ±3%/
3 mm, ±5%/5 mm and ±7%/4 mm (Table 2). Nine (75%)
of the 12 centers met the more stringent 3%/3 mm (90%
of pixels passing) gamma criteria that is commonly used
by institutions to perform their own IMRT QA as com-
pared to only 17% (2/12) of the RPC phantom irradiations.
Likewise, 12 (100%) of the 12 EORTC centers as com-
pared to 11 (92%) of the RPC phantom irradiation met the
5%/5 mm gamma criteria (90% of pixels passing).
RPC and VPP institutional dosimetry comparison
The RPC and institution VPP dosimetry measurements
for the two datasets were compared (Table 3). Using the
current RPC gamma criteria ±7%/4 mm (85% of pixels
passing) [2], the dose distributions from all 12 centers
meet the criteria using both the RPC and VPP measure-
ment data sets (Table 2). Using more stringent gamma
criteria, such as the ±5%/5 mm pass at the 90% pixel
level, the RPC had one dataset not meet the criteria
whereas all VPP datasets continue to meet the criteria.
Significant differences in the dosimetry data gamma evalu-
ations for the RPC sagital plane vs. the VPP gamma
evaluations were observed for the ±3%/3 mm gamma
criteria. A statistical trend was observed for the ±7%/
4 mm gamma criteria, but no dosimetric significantdifference was observed for the ±5%/5 mm gamma
criteria (Table 3).
Discussion
It is of paramount importance that institutions, within co-
operative groups, participating in multi-institutional pro-
spective studies, deliver RT per protocol and in a consistent
and comparable manner, so as not to corrupt the primary
end-point of the trial, obscure actual trial outcomes and
more importantly to avoid any undue treatment failure
and/or radiation-induced toxicity [7]. Several study groups
have been cognizant that the introduction of advanced ra-
diation technologies into clinical trials can jeopardize the
success of the trial unless the ability of the participating
institutions to utilize these advanced technologies in an
accurate and consistent manner is evaluated [9,10]. The
introduction of a new treatment modality or technology
has been shown to be error prone due to human errors
and lack of appropriate training. Reduced deviation rates
in clinical trials have been observed with various forms
of credentialing [2,4,11]. This is particularly relevant
for IMRT, for which the participating institutions must
show that they have the ability to generate dose distribu-
tion conformity to complex target structures with OARs
near the target per a protocol requirements [1].
This initial study comparing the gamma evaluations for
a single dosimetry plane between the RPC and VPP dos-
imetry measurements suggests that further investigation is
required prior to allowing IMRT credentialing for clinical
prospective studies in H&N cancer to be performed using
an institutions’ own phantoms whose data are centrally
evaluated. Critical issues that still need to be addressed in-
clude the inclusion of all of the dosimetry evaluations for
the whole credentialing process (e.g., for RPC CDC use
both film planes and the TLD results), data submission
issues for the VPP, the differences in the measurement
analysis techniques between RPC and VPP methods, and
method to designate a pass/fail criteria between the RPC
phantom CDC and the VPP. The second issue requires
that RPC phantom failures be compared to their VPP
counterpart to verify whether the institution’s own mea-
surements will not only identify passing CDCs but also
failing CDCs. Another issue is that RPC comprehensively
assess the whole QA procedure, ranging from the CT cali-
bration, data transfer, dose calculation- and dose delivery-
accuracy, which is obviously not the case of the VPP
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ate to the dosimetry gamma evaluation analysis must
be determined that is specific to the VPP method. One
cannot assume that the criteria used by one methodology
used for one center for a CDC would be applicable to
another center performing a CDC. Using an acceptance
criteria of ±3%/3 mm with a pixel pass rate of 90%, the
gamma evaluation analysis results obtained with the
RPCPH for the sagittal plane indicates a pass rate of 17%
while the VPP institution dosimetry gamma analysis using
the same criteria indicated a significantly different (75%)
pass rate (Table 2). There was however no significant
difference when analyzing at the ±5%/5 mm (90% of
pixels passing; pass rate of 92% vs. 100% for the RPC and
VPP, respectively) between the 12 RPC datasets and the
12 VPP datasets for this limited dosimetry analysis and
sample size. It is well know that commercial QA systems
have unequal sensitivities to detect dose errors. Interest-
ingly, the majority of our RPCPH-INSTPH discrepant re-
sults stemmed from the Delta 4 system (data not shown),
which is known to have suboptimal performances for
CDC [12]. It is crucial that more data be compiled before
any true judgment is made regarding the VPP credential-
ing process. Credentialing using the RPC phantom in-
cludes a much larger dosimetry dataset than evaluated
and used in this study and as such, no equivalence be-
tween the RPC and VPP CDC methods for the credential-
ing process can be made at this time.
The question posed by this study is whether the dos-
imetry comparisons from various TPSs and phantoms
used by each EORTC institution (Table 1) can be used
to verify IMRT planning and dose delivery for multi-
institution clinical trials as compared to the established
RPC phantom dosimetry measurement system. Normally,
IMRT credentialing is performed using remote auditing
tools, including but not limited to cylindrical target-non
target structures [13] or standardized anthropomorphic
phantoms [1]. These anthropomorphic phantoms, as used
by the RPC, provide uniformity in that they are all the
exact same design, use the same dosimeters, the dosime-
ters are all analyzed in the same manner with the same
precision, the dosimetry comparison software and regis-
tration is the same and a single set of acceptance criteria
is used for all irradiations. The phantoms irradiation stud-
ies provide an uniform basic end-to-end CDC on which
to assure comparability among multiple institutions. How-
ever, as an alternate CDC mechanism to the RPC IMRT
CDCs, this study investigated in a limited manner the pos-
sibility of performing IMRT credentialing using various
phantom types using the VPP paradigm by comparing the
dose distribution gamma evaluations in a single plane as
an initial step. This study has, however, some major limi-
tations and before the VPP paradigm is deemed acceptable
for CDC in prospective trials, a more extensive study anddataset are needed to validate the appropriateness of this
proposed dosimetry evaluation and credentialing process.
First, the limited number of centers in this study prevents
any true direct correlation between the RPCPH and INSTPH
CDC results. More results are warranted and a further
comparison of centralized phantom credentialing vs. virtual
phantom credentialing is needed. Second, the data from 6
out of 18 institutions (33%) could not be analyzed because
of data transfer incompatibilities that have to be resolved.
In two cases, the data could not be read by the evaluation
software. This problem might be solved in new versions of
either the measurement software or evaluation software. In
4 cases, the dataset was incomplete. The fact that, in our
analysis, a third of the data stemming from EORTC centers
could not be analyzed could be considered tantamount to
disproving the ability of the VPP to perform IMRTcreden-
tialing within the context of prospective trials. Truth to be
told, the retrospective design of this analysis put a lot of
pressure on medical physicists from EORTC centers to
obtain these data that were neither supportive of a com-
pulsory credentialing requirement process nor did benefit
patients treated in busy radiation oncology departments.
This problem could be solved with the introduction of
prospective credentialing as is performed for NCI funded
clinical trials, such that without providing the full dataset,
trial participation is not granted. The VPP methodology
will be prospectively tested in the new EORTC lung
cancer study (www.eortc.org/research-groups/radiation-
oncology-group/recent-achievements). Third, in this study
only homogeneous VPP phantoms were used and as such,
the TPS’s ability to correctly calculate dose in an inhomo-
geneous geometry was not tested. However, one can re-
quire institutions to incorporate additional heterogeneities
in the phantom design within a VPP procedure if desired.
Finally, the measurement precision of each institution
with respect to their phantom and measurement proced-
ure is not known and can be quite different depending on
the dosimetry equipment available and expertise of the
staff. This might lead possibly to false negative or false
positive credentialing results. While a false negative result
can be solved by a new measurement, a false positive re-
sult cannot be detected as easily as with a centralized
phantom (i.e., RPC credentialing) with a small measure-
ment uncertainty. The need to include credentialing phan-
tom failures and compare those results to the VPP CDCs
is necessary to ascertain the validity of the VPP process.
Credentialing through a VPP should thus never be per-
formed as the only QART check within a trial. Beam Out-
put Audits should always be required, as it is currently for
most institutions participating in clinical trials.
This study is essentially the first step in a proof of con-
cept and feasibility study to perform virtual credentialing,
however much work is still to be done. The use of stan-
dardized anthropomorphic phantoms has undeniably
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phantoms only. The uniformity and quality of data that
are collected centrally is unquestionable. This procedure
is a comprehensive test of a center’s ability to image, plan
and treat a patient. The credentialing procedure has been
routinely performed for over a decade and has provided a
contemporary benchmark that future procedures cannot
exceed; rather, alternative credentialing procedures should
try to attain the same level of accuracy, at decreased pro-
cedural costs or time. There is the need to continually
evaluate this particular credentialing process to determine
if there are more efficient methods.
Depending on the specific protocol and its requirements
for treatment delivery, the method of credentialing should
be identified that best provides the most consistent patient
data population for the trial analysis. More specifically,
errors in TPS software’s inadequate modeling of the
penumbra at MLC leaf ends or inadequate QA of multi-
leaf collimator should be verified. These potential errors
could potentially be identified also by institutional creden-
tialing, however the data from > 1000 IMRT H&N phan-
tom irradiations suggest that this is not the case since
nearly 20% of the institutions failed the RPC phantom ir-
radiation test using a generous criteria [3]. Incorrect out-
put factors and percent depth dose data, entered by the
institution, cannot however be thoroughly verified by an
institutional credentialing process without central supervi-
sion and absolute dosimetry measurements. Moreover,
incorrect systematic application of QA calculations or
measurements can be diligently identified by the RPC’s in-
dependent audit, but not by the institution itself. These
types of dosimetric violations should be routinely identi-
fied by the local QA process of participating institutions
which have their own QA programs, but because of
human error, workload, to name a few, many of these
dosimetric discrepancies may go undetected. The RPC’s
end-to-end phantom CDC also has drawbacks in that it is
difficult to identify the specific component in the chain of
events that causes the irradiation failure since it is a com-
posite QA check. As such, the need for an institution to
have a rigorous QA program to identify to verify individ-
ual dosimetric components of an RT delivery is para-
mount, but each institution should also have a method,
such as an independent QA check, to verify the whole de-
livery process.
Noteworthy, RPCPH and INSTPH CDCs are 2D/absolute
and relative dosimetry measurement verification systems,
respectively. As such, the measurements from these sys-
tems represent only a sparse sampling of the complete 3D
treatment volume. QA standards for IMRT QA could be
improved by incorporating 3D dosimetry techniques.
Sakhalkar et al. reported on the feasibility of relative 3D
dosimetry using the RPC phantom for credential testing
[14]. Using a 98% pixel level at the ±4%/3 mm distance toagreement in the axial central axis plane, an excellent
agreement was observed between the 3D and 2D gamma
maps inter-comparison. Both the phantoms and VPP
CDCs could be further refined using 3D gamma maps and
incorporated within the credentialing program of future
prospective trials to provide an improved assessment of
an institution’s ability to deliver radiotherapy doses accur-
ately and consistently. Also, incorporation of e.g. breathing
motion and heterogeneities in the credentialing procedure
also adds to the complexity of the overall credentialing
process, as it requires substantial skill’s analysis to handle
these phantoms. In contrast, centers in Europe that have
introduced treatment techniques incorporating gating or
tracking motion management generally have acquired
specific QA phantoms for this. Thus, the use of a VPP
could potentially also allow a faster credentialing and
introduction of these techniques in EORTC clinical trials
if the VPP can be made to be uniform in its data collection
and assessment. Moreover, these phantoms might also be
used to test the 4D CT imaging capabilities of these insti-
tutions [15].
In conclusion, IMRT dosimetry gamma evaluations
for a single plane of data evaluation for a H&N pro-
spective trial using the institutional phantom measure-
ments showed agreement at the gamma index criteria
of ±5%/5 mm (90% of pixels passing) in this analysis that
involved a limited number of VPP measurements. Gamma
indexes also showed agreement between RPC and VPP
metrics at the ±7%/4 mm (85% of pixels passing) but more
VPP data sets are needed before a definite conclusion
can be reached since we cannot assume that the cri-
tieria levels being used by the two evaluations, RPC and
VPP, would be the same as the means to compare the two
techniques.
Additional file
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